CXCR2
C-X-C chemokine receptor type 2
As of the edition of 20 October 2026, CXCR2 (C-X-C chemokine receptor type 2, UniProt P25025) has 12 drugs tested at it and 7 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25025
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 18
- Disease areas
- Lungs and airways; Cancer; Immune system; Skin and connective tissue; Digestive system; Hormones; Infections; Blood and lymph
- Registered trials of its drugs
- 91
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 4 |
| Stopped | 7 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Reparixin | Stopped | Phase 3 | none listed |
| SX-682 | Active | Phase 2 | none listed |
| AZD5069 | Stopped | Phase 2 | none listed |
| Danirixin | Stopped | Phase 2 | none listed |
| Ladarixin | Stopped | Phase 2 | none listed |
| Navarixin anhydrous | Went quiet | Phase 2 | none listed |
| Vimnerixin | Stopped | Phase 2 | none listed |
| Elubrixin | Went quiet | Phase 2 | none listed |
| MGTA-145 | Stopped | Phase 2 | none listed |
| AZD-5122 | Went quiet | Phase 1 | none listed |
| AZD8309 | Went quiet | No phase stated | none listed |
| DF2755A | Stopped | Phase 1 | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Engaged | 2 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Aristea Therapeutics | Route A |
| GSK | Route A |
| Merck & Co. | Route A |
The other 4 companies at CXCR2
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at CXCR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.